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ABSTRACT
Objective The goal of this study is to investigate women’s preferences and information needs for routine
implementation of fetal Rhesus D (RhD) typing using cell-free fetal DNA.
Methods A questionnaire was developed following focus groups and interviews with both health professionals and
RhD negative (RhD) women offered fetal RhD genotyping within a research study and distributed to RhD women
attending routine antenatal appointments in four National Health Service hospitals. Current knowledge of blood
types, anti-D administration, fetal RhD genotyping and future practices were explored.
Results A total of 19 respondents participated in interviews and focus groups, and 270 respondents completed the
questionnaires. Questionnaire respondents overwhelmingly felt that the test should be offered to all RhD women
(92.1%), and 75.9% said that they would accept this test. Most were happy to have the test even if it involved extra
blood tests (89.3%) or appointments (79%). The knowledge of blood groups was poor. Although 90.7% knew that
the baby could have a different blood group from themselves, only 34% knew that blood groups are inherited from
both parents. More than 40% were not aware that anti-D would not be required if their baby was RhD.
Conclusions Women would welcome the introduction of routine fetal RhD genotyping. Information leaﬂets and
training of midwives will be essential for implementation to ensure good understanding regarding testing. © 2013 The
Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
Supporting information may be found in the online version of this article.
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INTRODUCTION
Toprevent alloimmunisation ofRhesus negative (RhD)mothers
carrying a Rhesus positive (RhD+) fetus, the National Institute
for Health and Clinical Excellence recommends that routine
antenatal prophylaxis with anti-D immunoglobulin should be
offered to all RhD pregnant women in the third trimester
as well as after birth and following events associated with
fetal maternal haemmorhage.1 As a result, the incidence of
haemolytic disease of the newborn caused by alloimmunisation
has fallen dramatically. However, in the UK, about 40% of RhD
women (around 40000 per year) carry an RhD fetus and thus
receive anti-D unnecessarily.2 Anti-D is produced from pooled
plasma from large numbers of RhD donors who have been
transfused with RhD+ red cells to stimulate the production of
RhD antibodies3 and thus carries a very small risk of transmission
of human blood-borne viral or prion diseases.4
The identiﬁcation of cell-free fetal DNA (cffDNA) in maternal
blood from early in pregnancy5 has allowed the development
of non-invasive prenatal testing (NIPT) to determine the fetal
RhD genotype in RhD mothers by analysing a maternal
plasma sample.6 This test has been used clinically in England
for over a decade to direct care for sensitised RhD women
who would require additional monitoring and potential
treatment if they were carrying an RhD+ fetus.6 Advances in
technology mean testing can now be carried out accurately
and efﬁciently on a larger scale using automated techniques.7,8
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Indeed, routine testing at 25weeks gestation has already been
successfully introduced into antenatal care in Denmark.9
Recent guidance from the National Institute for Health
and Clinical Excellence has recommended the exploration of
routine antenatal fetal RhD genotyping.10 Here, we investigate
how women view current information about blood groups,
anti-D administration, the new cffDNA test and how they
would like it offered in practice. This study forms part of a larger
study developing standards for the implementation of routine
fetal RhD genotyping in the UK (antenatal determination of
fetal RhD status using cffDNA in the maternal circulation
before 20weeks gestation: is routine application practical
and beneﬁcial? PB-PG-0107-12005).
METHODS
Focus groups and interviews
To develop questionnaires for the main study, we used focus
groups and one-to-one interviews to explore the views and
experiences of RhD women and health professionals at one
London hospital. A purposive sampling method was used for
recruitment. The RhD women were those who had been
previously offered with fetal RhD genotyping as part of an
ongoing intervention study. The study invitation and infor-
mation sheet were provided at the 28-week appointment, and
participants were interviewed by the lead researcher (KO).
Health professionals were identiﬁed from staff lists, invited in
person and interviewed by one of two researchers (KO and
CC) or took part in one of two focus groups. The study was
approved by the National Research Ethics Committee London
Bentham (07/H0714/128).
A semi-structured discussion guide was used to ascertain
perceptions of the current antenatal information regarding
RhD and anti-D administration for RhD women, explore
views and opinions regarding routine fetal RhD genotyping
and identify preferences for implementation into routine
practice (see online Appendix 1). The interviews and focus
groups were recorded, transcribed verbatim and analysed
using thematic analysis.11 To ensure inter-rater reliability,
the transcripts were read and coded independently by two
other researchers (MH, CC) with themes identiﬁed and
agreed collectively. Data collection ceased when no new codes
were identiﬁed.
Questionnaire study
Design
The questionnaire was developed using signiﬁcant themes
identiﬁed from the focus groups and interviews. Questions
included views and preferences regarding fetal RhD typing
(n= 4), current knowledge of blood group, anti-D and its
administration (n=15), current sources of information (n=8)
and demographics and characteristics of the participants (n=9).
A four-item Likert scale was used for ﬁve of the questions to
assess understanding of current information and knowledge and
beliefs. A paragraph describing routine fetal RhD genotyping
was given in the questionnaire (online supplementary data, S1).
The questionnaire was initially piloted on 20 women, and no
changes were needed.
Data collection
The questionnaire was distributed in four National Health
Service hospitals, one London teaching hospital and three
regional hospitals. Research midwives at each site invited
RhD women to ﬁll in the questionnaire whilst waiting for a
routine antenatal appointment any time after 12weeks gestation.
Data analysis
Data were entered onto an Excel spreadsheet and analysed
using SPSS statistics version 17.0. Descriptive statistics were
used to analyse individual questions, which included the 15
questions testing the knowledge of blood group, anti-D and
the reason why anti-D is given. One point was given for each
correct answer and totalled to give an overall knowledge score
ranging between 0 and 15. A one-way analysis of variance was
used to test for differences in knowledge scores compared with
several variables. A t-test was used to test if knowledge scores
varied in the second and third trimester. Chi-square tests were
carried out to compare answers to speciﬁc questions in the
second and third trimester.
Spearman correlation was used to determine whether there
was a relationship between knowledge scores for anti-D and
blood group compared with the perception of how useful the
information was, the level of information provided and how
knowledgeable participants believed themselves to be.
Women were allowed to give more than one response for the
questions relating to how they receive information and reasons
for accepting or declining NIPT. For these questions, descriptive
analysis was used with percentages being calculated from the
total number of responses. One question asked women to rank
their answers in order of importance. Some women only ranked
those they rated as most important, and these responses were
included. This question was analysed by taking each option
individually and calculating how many people had ranked it
at each level.
RESULTS
Qualitative results
Participants
Six women and 13 health professionals recruited from one
London hospital participated. Six one-to-one interviews were
held with RhD women, two with obstetric registrars and
two with midwives. Two focus groups were held with midwives
(n= 9). The women represented a variety of experiences with
regard to receiving different fetal RhD genotyping results and
decisions regarding anti-D (Table 1). Although only six women
were included, this was sufﬁcient to reach a point where no
new themes were identiﬁed.
Perceptions of routine fetal genotyping
Several themes emerged regarding perception of the new test
and how it should be offered into practice.
Beneﬁts of fetal RhD genotyping
All participants felt that the new test was a positive development
that should be offered to all RhD women (Table 2; quotes 1
and 2). Health professionals felt that, overall, women were not
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concerned about anti-D being a blood product. Women
considered the beneﬁts of anti-D outweighed any risks (Table 2;
quote 3) but were keen to avoid unnecessary treatment (Table 2;
quotes 4 and 5).
Service delivery
Health professionals felt that although offering the test early in
pregnancy was important, offering additional appointments
was not practical because of stafﬁng levels and time required.
Concern was raised that time constraints would make it
difﬁcult to discuss at booking (Table 2; quote 6). The routine
16-week appointment was suggested as a good opportunity
to offer the test to RhD women. However, most women were
happy to have a separate blood test and attend for an extra
appointment if necessary (Table 2; quote 9).
Test accuracy
All participants thought that accuracy of the test was highly
important (Table 2; quotes 11 and 12) and a key factor in
the acceptance of the test. Women want to be offered the test
at a time when it is most accurate even if this meant it was
later in pregnancy. Two women felt that they would still
rather have anti-D ‘to be on the safe side’; however, these
women said that if the test was proven to be accurate and
offered as part of routine care rather than on a research basis,
then they would feel conﬁdent about not having anti-D.
Health professionals were concerned about false negative
results and the potential for babies developing preventable
haemolytic disease of the newborn.
Information and education
Information and education were also major factors highlighted
by all participants. Women felt that the amount of information
given in pregnancy can be difﬁcult to absorb, and although
they said that they did not always read it, they still felt that
receiving simple and succinct written information to the
appointment where the test is offered was important (Table 2;
quotes 13, 16, and 17). Diagrammatic information was generally
preferred (Table 2; quotes 14 and 15).
Midwives recognised that they would be the primary source
of information about the test and wanted extra training,
written and face-to-face. Notably, health professionals felt that
most women accept whatever is offered to them as routine
care (Table 2; quote 10), an observation conﬁrmed by women
who stated that they would accept their recommendations
Table 1 Interview participants: Rhesus negative women
Name Parity Predicted RhD status using NIPT Anti-D
Woman 1 0 Positive Yes
Woman 2 0 Negative Yes
Woman 3 0 Positive Yes
Woman 4 0 Negative Declined
Woman 5 0 Positive Yes
Woman 6 2 Negative Declined
RhD, Rhesus D factor; NIPT, non-invasive prenatal testing.
Table 2 Quotes from participants of interviews and focus groups
Quote number Participant Quote
1 RhD woman ‘. . .Oh I think it would be great absolutely and I would be all for it.’
2 Midwife ‘. . .they are very excited that you can ﬁnd out the blood group of the baby, before the babies born with
no invasive procedure.’
3 RhD woman ‘I am aware of that risk and I think the beneﬁts outweigh the risk.’
4 RhD woman ‘..you know if you don’t have to have a blood product I don’t see why you should be given it.’
5 RhD woman ‘..Yes it is a blood product, and I think ideally you know if you can avoid having blood products that’s great. . .’
6 Midwife ‘. . . when you have so many bookings squished into a clinic and you have all these documents and all these things
to go through.’
7 Midwife ‘I think it will change practice positively providing that you’ve got a good accuracy rate.’
8 RhD woman Blood tests. . ..‘I think there was an extra one I’m not sure, but that doesn’t bother me. . .’
9 RhD woman ‘I think if it becomes routine that they know they have to go and have the blood test then they will just accept it.’
10 RhD woman ‘I guess pretty close to 100% accurate, otherwise then if you don’t have the injection you are risking the health
of the child aren’t you’
11 RhD woman ‘I’m not saying I haven’t been given all the information but there is just too much to take in during pregnancy’
12 Midwife ‘. . .so I try to make it more graphical then because its difﬁcult to explain what its all about.’
13 RhD woman ‘. . .the booklet one was really good, that kind of taught me because I didn’t know about it before . . .it’s still a bit mind
boggling but easier when its in a diagram.’
14 Midwife ‘I think when the information leaﬂets were being sent to them then it made our job easier. Because they would have
read about the information and at least they are well informed.’
15 RhD woman ‘I think it’s always nice to have something written down so you can refer to it after if you don’t take it all in at the time.’
RhD, Rhesus D negative.
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(Table 2, quote 8) as they trusted health professionals to do
what was best for women.
Quantitative results
Participants
A total of 270 of the 287 women approached completed the
questionnaire (response rate: 94%), which were developed
using the themes emerging from the qualitative study. Four
questionnaires were excluded because the participant was under
12weeks gestation. Demographic information of participants is
available as supplementary data (S3).
Current knowledge about Rhesus D status and anti-D
The average knowledge score (on a scale of 0–15) was 8.7
(SD = 3.44, range = 0–15): responses are shown in Table 3.
Knowledge score comparisons with several variables are
shown online in Table S3. There was a signiﬁcant association
between education and knowledge score [F (5, 240) = 7.956,
p< 0.001]. Post hoc tests showed that women with a degree
[M = 10.20, 95% CI (9.54, 10.85)] scored signiﬁcantly higher
than women with either no qualiﬁcations [M=6.53, 95% CI (5.51,
7.56)] p=0.001 or educated to general certiﬁcate of secondary
education level [M=7.43, 95% CI (6.63, 8.22)], p< 0.001.
There were signiﬁcant differences in knowledge score in
relation to whether women had anti-D in their pregnancy
[F (2, 255) = 13.027, p< 0.001]. Post hoc comparisons showed
that women who were unsure if they had received anti-D
(M = 4.42, SD = 3.605) scored signiﬁcantly lower than both
women who knew they had received anti-D (M = 9.26, SD =
3.160) p< 0.001 and those that knew they had not received
it (M = 8.45 SD = 3.290).
When questions were analysed individually, women in their
third trimester were more likely to know that they would not
need anti-D if they knew their baby was RhD [65.6% vs 48.1%
(p< 0.005)] and that they would only be given anti-D after
birth if their baby was RhD+ [59.8% vs 39.7% (p< 0.005)].
Results showing variations across trimesters are shown online
in Table S4.
Current sources of information
The main source of information for women was their midwife
(50.3%), followed by the hospital information leaﬂet (17.7%),
Internet (10.8%), family and friends (9%), doctor (7.5%) and
other sources including books and prior knowledge through
education or previous pregnancies (4%). Three women said they
had not received any information regarding their blood group.
The majority of women (68.50%) felt that they had received
enough information about their blood group and had found
it useful (80.7%). Half of the women (50.6%) felt they knew ‘a
little bit’, and 31.8% felt they were ‘quite’ knowledgeable about
their blood group. The majority of women (80.1%) had been
told about anti-D in their current pregnancy. Signiﬁcantly,
more women in their third trimester had been told about
anti-D compared with those in their second trimester (86.5%
vs 74.2%, p< 0.05). The majority of women felt they had been
given enough information about anti-D (67.7%). However, a
signiﬁcant number felt they needed more information (32.3%).
Women were more likely to feel that they had been given
enough information if they were in their third trimester (76.3%
vs 59.4% p< 0.005). Generally, women found the information
that was provided about anti-D useful (79.2%).
Opinions on routine fetal RhD genotyping
Women were overwhelmingly in favour of the test being
offered routinely to all women (92.1%). However, there was
some uncertainty when asked if they would accept the test
themselves (75.9%). The possible reasons for declining the test
are given in Table 4.
Table 3 Fifteen questions testing current knowledge of blood group and anti-D
Knowledge questions Correct Wrong Unsure
1) I inherited my blood group from both parents 33.7% (91) 33.3% (90) 32.2% (87)
2) I will be offered an anti D injection in pregnancy 90.0% (243) 3.3% (9) 6.3% (17)
3) My baby could have a different blood group from me 90.4% (243) 1.1% (3) 8.1% (22)
4) Rhesus negative means you do not have the D antigen on your red blood cells. 38.1% (103) 5.9% (16) 55.6% (150)
5) Is anti D a blood product? 41.9% (113) 33.7% (91) 23% (62)
6) Can anti D cause an allergic reaction 32.6% (88) 7% (19) 57.4% (155)
7) Anti D is made from human blood plasma 27.4% (74) 4.1% (11) 66.3% (179)
8) Anti D is given by injection 91.1% (246) 0.4% (1) 6.7% (18)
9) Anti D is strictly controlled to avoid transmission of blood borne infections 51.1% (138) 3.3% (9) 43.7% (118)
10) If you are RhD and your baby is RhD would you need Anti D 55.9% (151) 17.4% (47) 24.4% (66)
11) Anti D is given to prevent the body producing antibodies 68.9% (186) 7% (19) 21.9% (59)
12) Anti D is given to protect babies in future pregnancies 69.3% (187) 9.3% (25) 19.3% (52)
13) Anti D is given because the baby might be Rhesus positive 68.5% (185) 4.1% (11) 24.4% (66)
14) Anti D is given because the baby might be Rhesus negative 59.6% (161) 8.1% (22) 27.4% (74)
15) After my baby is born, I will be given anti D if my baby has a positive blood group 48.9% (132) 26.3% (71) 23% (62)
aValues reported as % (n). Some responses were missing therefore total values may not add up to 100%.
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There was a signiﬁcant difference in the knowledge score for
women who were unsure if they would accept the test and
those that would accept the test (p= 0.002). Women who were
unsure if they would accept fetal RhD genotyping had
signiﬁcantly lower knowledge scores [M= 7.64, 95% CI (6.66,
8.63)] than those who would accept the new test [M= 9.49,
95% CI (8.99, 9.99)], p = 0.002. Other comparisons and
demographic characteristics were not signiﬁcant.
Preferences for how fetal RhD genotyping should be offered
Themajority of women (95.9%) would rather have the blood test
performed at the same time as other routine blood tests.
However, they would be happy to have an extra blood test
(89.3%) if it was necessary. Most women would want the
opportunity to discuss the test with a midwife (89%) and would
be willing to have an extra appointment if required (79%).
Women ranked the test accuracy, having enough information
and being able to discuss with a midwife most highly (Figure 1).
Information preferences
Most women want to receive information from their midwife
(59.7%) or have written information in a leaﬂet (34.5%) rather
than accessing the information on the hospital website
(4.6%). Most wanted to be told about the test at the booking
appointment with the midwife (46.3%), with 23.1% preferring
to receive information in the post with the initial booking
appointment letter and 21.6% wanting it posted with the
results of their blood test. There was a clear preference for
receiving the information prior to the day of the test (91%).
Just under half the women (47.2%) said that the amount
of information provided in the study leaﬂet was sufﬁcient,
36.7% wanted more information and 16.1% were unsure. The
following topics were identiﬁed as additional information that
would be useful:
1. Risks or side-effects to mother and baby
2. Timing of tests, if extra appointment needed
3. Implications of results
4. How the test works
5. Accuracy and implications if the test result is incorrect
6. Being able to discuss the test with a midwife/health professional
7. General information about blood group, why the test is necessary, risks
of anti-D
8. Whether any other information can be found out from the test.
DISCUSSION
In this unique study, we have clearly demonstrated that there
is enthusiasm from both women and health professionals for
Table 4 Views of potential routine fetal Rhesus D typing
Total (n=270)a No Yes Unsure
Should fetal RhD typing be offered to all RhD women? (n=215) 0.9% (2) 92.1% (198) 7% (15)
Would you accept the test? (n=216) 2.8% (6) 75.9% (164) 21.3% (46)
Would you need further information about the test? (n=267) 47.2% (126) 36.7% (98) 16.1% (43)
How do you prefer to receive information?b
Midwife 59.8% (104)
Hospital information leaﬂet 34.5% (60)
Internet 4.6% (8)
Other 1.1% (2)
When would you want to receive information?b
In post with booking letter 23.1% (31)
At booking appointment with midwife 46.3% (62)
In the post with blood group results 21.6% (29)
On the day of NIPT 6.7% (9)
Other 2.2% (3)
Why would you want the test?b
Rather avoid anti-D 32.7% (88)
Rather avoid injection 22.3% (60)
To know more about the baby as possible 28.6% (77)
If recommended by midwife 16.4% (44)
Why would you not want the test? b
Would not want extra blood test 20.8% (5)
Would want anti-D to be on the safe side 37.5% (9)
Would want more information 41.7% (10)
aTotal number responses shown for individual questions (n).
bRespondents could select more than one answer, % have therefore been calculated from the total number of responses for each answer.
RhD, Rhesus D; NIPT, non-invasive prenatal testing.
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routine fetal RhD genotyping using cffDNA in maternal blood,
regardless of whether it will require extra blood tests or visits.
However, health professionals felt that it should be offered with
other routine appointments to minimise resource implications,
an observation that is supported by the economic evaluation
performed in this study.12
The strength of the study is the use of qualitative data from
women with experience of fetal RhD genotyping and health
professionals to develop the questionnaire together with the
quantitative data on preferences from a large number of
RhD women attending four different hospitals. This work
expands the current research on fetal RhD genotyping which
to date has focused on technology development, test accuracy
and economics.6–8 Previous research into views and experiences
of the use of cffDNA tests is based on tests already in clinical
practice and includes women13,14 and health professionals’15
views on fetal sex determination for clinical indications. Other
studies have looked at public,16 pregnant women17,18 and
health professionals’19 views of NIPT using cffDNA for Down’s
syndrome and other conditions. These studies found that NIPT
is viewed as a positive step in prenatal diagnosis for Down’s
syndrome and genetic conditions.
This study found that women would be more likely to accept
fetal RhD genotyping if they felt conﬁdent about its accuracy.
Women with lower knowledge scores were less certain whether
they would accept the test. It is concerning that knowledge
scores showed a lack of understanding of current care regarding
anti-D in several areas. Women were unsure why anti-D is given
and that their baby could have a different blood group from
them. This knowledge improves in the third trimester, most
likely because information is given at the time of anti-D
administration at the beginning of the third trimester. Women
wanted to know why routine RhD genotyping is beneﬁcial, and
thus understanding blood group inheritance and why anti-D
prophylaxis is only necessary if the baby is RhD+ is important.
Women showed a preference for receiving written information
in the post and speaking to the midwife before being offered
the test. This reﬂects ﬁndings from a Dutch study evaluating
screening programmes for non-Rh red blood cells; when
asked about their information needs, women desired written
information and prioritised having information on the clinical
implications for both mother and child.20 One of the key
issues women wanted addressed was whether fetal RhD
genotyping testing posed a risk to mother or baby. The test
was described as a ‘normal blood test’. However, women were
still concerned about risk. Furthermore, as we are using the
baby’s DNA, there was also concern that we could potentially
reveal other information about the baby.
A notable theme from the qualitative data was women being
willing to accept whatever was recommended to them by the
midwife or presented as routine care. Questionnaire ﬁndings
showed 16.7% of women felt that they would accept the test
if it was recommended to them by the midwife. This is a similar
ﬁnding to a study that investigated women’s interest and
expected uptake of NIPT using cffDNA for prenatal diagnosis,
which found that 20% of respondents would do what their
doctor recommended.17
These ﬁndings indicate that health professionals, in par-
ticular midwives, will need to ensure that complete and
balanced information is given to women to allow them tomake
an informed decision regarding fetal RhD genotyping and anti-
D administration. Current blood group information leaﬂets
could be developed to include information about fetal RhD
genotyping. Information should be clear and concise and
presented at a relevant time. This study cannot determine
when in the care pathway this test should be offered, but
inherently, the earlier in pregnancy, the better to avoid
unnecessary anti-D administration for early sensitising events.
As information regarding the mother’s own Rh type is needed
before fetal RhD genotyping can be interpreted, sending the
information with the booking blood results seems appropriate
and is a time when there is less information being given about
other aspects of pregnancy.
Study limitations
In this study, we attempted to gather the views and preferences
of a cross-section of women by recruiting from four different
hospitals in different regions of the UK. However, several issues
may limit how representative our ﬁndings are. For example,
the majority of pregnant women who took part in this study
were White, and women from ethnic minority groups are
under-represented.
Factors ranked as important when being offered routine fetal RHD typing: 
1 = most important and 5 = least important
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Figure 1 Factors ranked as important when being offered routine fetal RhD typing
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A small sample of health professionals and RhD women
took part in the focus groups and interviews: These were all
based at one hospital and only had experience of fetal RhD
genotyping being offered on a research basis. Other hospitals
may have different protocols, and fetal RhD genotyping may
be offered differently when introduced routinely into practice.
Therefore, their views and experiences may be speciﬁc to their
own experience. The study reﬂects women’s stated preferences
and may not in fact reﬂect future attitudes and uptake of fetal
RhD genotyping. It will be important to research the best ways
to provide information and education for women.
CONCLUSIONS
This is the ﬁrst study to investigate health professionals and
women’s views and opinions of routine fetal RhD genotyping.
Although we have shown an overwhelmingly positive response,
we have also demonstrated signiﬁcant weakness in delivery of
information regarding the current information on Rh blood
groups and anti-D administration. Before being offered this
new test, women want timely information on its beneﬁts, risks,
accuracy and implications, making development of information
leaﬂets and health professional training key to routine clinical
implementation. This work is critical for the development of
policies and guidelines for the introduction of fetal RhD
genotyping into routine care.
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WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Technological advances mean that there is now potential to offer
routine fetal RhD typing using cell-free fetal DNA to all Rhesus
negative women. This will mean that anti-D can be targeted to
women carrying a Rhesus positive baby.
WHAT DOES THIS STUDY ADD?
• This unique study shows that women and health professionals hold
positive views regarding the introduction of routine fetal RhD
genotyping using cell-free fetal DNA. Women’s current knowledge
of Rhesus blood groups and anti-D administration was found to be
limited. Development of information leaﬂets and health professional
training will therefore be critical for successful implementation.
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